

Additional Leadership and Partner Quotes

Board and Leadership

- **Michel Goldman, Founding Executive Director of the Innovative Medicines Initiative:** “We believe in the power of partnerships to accelerate innovation in healthcare, especially in a disease as complex and challenging as Alzheimer’s. DAC’s role in orchestrating a collaboration on the scale needed to change the course of this devastating disease is critical.”
- **Dr. Freda Lewis-Hall, Founding Board Member, DAC and former Chief Patient Officer, Executive Vice President and Chief Medical Officer, Pfizer:** “I believe in DAC’s mission focusing on patients and their families. DAC is bringing together experts and organizations from every possible skill and perspective to attack a complex and challenging disease from multiple angles, united by a common focus on advancing specific tactics that have the most promise of delivering results that matter most for the individuals, families and communities that are vulnerable to this terrible disease. While we face a long fight ahead against Alzheimer’s, DAC is ensuring that no one is fighting it alone.”
- **David Bloom, Professor of Economics and Demography, Harvard T.H. Chan School of Public Health:** “Alzheimer’s disease poses a virtually unchecked threat to our aging global population, and it will continue to proliferate among those least equipped to fight it as the center of gravity for Alzheimer’s and other dementias shifts from high-income countries to low- and middle-income countries. Given the rising trajectories of this health, social and economic burden, it makes humanitarian and economic sense to invest substantially more resources in R&D on a global scale.”
- **Dr. Geoffrey Ginsburg, Founding Co-Chair of the International One Hundred K+ Cohorts Consortium (IHCC) and Professor of Medicine, Biomedical Engineering, Biostatistics and Bioinformatics, Duke University:** “The IHCC is pleased to partner with the Davos Alzheimer’s Collaborative and advance our shared mission of scaling research globally to fuel innovation and discovery. The cohort leaders in our network around the world recognize the growing burden of Alzheimer’s disease and are eager to work with DAC to find solutions.”

Regional Partners

- **Nancy Ip, Vice-President for Research and Development, The Morningside Professor of Life Science and Director of the State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology:** “The number of people living with dementia in the Asia Pacific region is expected to triple between now and 2050. While Alzheimer’s research and awareness is on the rise in many areas, there is an urgent need to accelerate innovation in treatments and healthcare system preparedness. My institution and others have long recognized the importance of global collaboration to meet this need, and partnering with DAC will allow us to expand those collaborations like never before.”
- **Dr. Ricardo F. Allegri, Professor of Neurology, School of Medicine, Universidad de Buenos Aires and Head of Cognitive Neurology, Neuropsychology and Neuropsychiatry, Instituto de Investigaciones Neurológicas Fleni, Buenos Aires, Argentina:** “Many countries in Latin America are already experiencing the growing burden of Alzheimer’s, and the only way to face this threat is to face it together. By working with DAC to establish collaborations in Argentina, we hope to lead the way toward a future where we combine our capabilities and best practices to turn the tide of this disease.”

Program Leaders

- **Rhoda Au, Director, Global Cohorts, DAC; MPI, Framingham Heart Study Brain Aging Program and Professor, Boston University School of Medicine and School of Public Health:** “Alzheimer’s cases are rising rapidly worldwide, including in low- and middle-income countries, yet most research efforts are concentrated in North America and Western Europe. Scientists around the world are being left without access to data or tools to research the disease in their own communities. By creating a diverse global cohort and piloting 21st-century technologies like smartphones and at-home test kits, we are working to make Alzheimer’s research accessible to everyone, because there can be no innovation without inclusion.”

- **John Dwyer, Director, Clinical Trials, DAC and President, Global Alzheimer's Platform Foundation:** "We're excited to continue expanding our clinical trial support network into other regions and countries to advance more robust and inclusive global Alzheimer's clinical research. We are expanding our North American platform into Europe and are building the roadmap to expand operations into other regions."
- **Phyllis Ferrell, Acting Director, Healthcare System Preparedness, DAC and Global Head, External Engagement, Alzheimer's and Neurodegeneration, Eli Lilly & Company:** "To improve care for people with Alzheimer's and those at risk of cognitive impairment, our healthcare systems need to evolve significantly to keep pace with the scientific advancements in the field. The COVID-19 pandemic has highlighted the shortcomings and inequities of our current care model for older persons and the need for change is more urgent than ever. Our role is to bring healthcare partners from around the world together to pilot innovative solutions, share learning and harness that collective momentum so we can build better systems for our aging population worldwide."

###